Patents by Inventor Daniel Getts

Daniel Getts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210299172
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2021
    Publication date: September 30, 2021
    Inventors: Daniel Getts, Yuxiao Wang
  • Engineered phagocytic receptor compositions and methods of use thereof
    Patent number: 11026973
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: June 8, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • Engineered phagocytic receptor compositions and methods of use thereof
    Patent number: 11013764
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 25, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • Therapeutic cell compositions and methods of manufacturing and use thereof
    Patent number: 10980836
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: April 20, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200345774
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2020
    Publication date: November 5, 2020
    Applicant: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200345773
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2020
    Publication date: November 5, 2020
    Inventors: Daniel Getts, Yuxiao Wang
  • Immune-modifying nanoparticles for the treatment of inflammatory diseases
    Patent number: 9913883
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 13, 2018
    Assignee: COUR Pharmaceuticals Development Company
    Inventor: Daniel Getts
  • COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
    Publication number: 20160166664
    Abstract: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.
    Type: Application
    Filed: July 23, 2015
    Publication date: June 16, 2016
    Applicant: Northwestern University
    Inventors: Stephen Miller, Russell L. Bromley, Michael A. Pleiss, Daniel Getts, Aaron Martin
  • COMPOSITIONS AND METHODS FOR ANTIGEN-SPECIFIC TOLERANCE
    Publication number: 20150150996
    Abstract: The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.
    Type: Application
    Filed: June 6, 2013
    Publication date: June 4, 2015
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Stephen Miller, Michael A. Pleiss, Daniel Getts, Aaron Martin
  • COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
    Publication number: 20120076831
    Abstract: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such as autoimmune disease, transplant rejection and allergic reactions.
    Type: Application
    Filed: January 20, 2010
    Publication date: March 29, 2012
    Inventors: Stephen Miller, Russell L. Bromley, Michael A. Pleiss, Daniel Getts, Aaron Martin